Location: 34 Chambers Street, 115
Speaker: Shahram Hejazi
In this 2-hour workshop, Shahram Hejazi, Keller Center Entrepreneurship Specialist, who teaches the popular "EGR 395: Venture Capital and Finance of Innovation," will present an overview of financial accounting for early stage ventures. The interactive session will focus on financial skills that are most needed for startups, such as developing profit and loss statements and understanding cash flow projections. Brunch will be served and registration is required.
Audience: undergraduate students, graduate students, postdocs, and alumni
10:45am - Brunch
11:00am - Workshop begins
1:00pm - Workshop ends
Shahram Hejazi, is a life science investor and entrepreneur with general management experience in both early-stage ventures and large global companies. Over his 25+ year career, Shahram has founded and/or directed the growth of more than two dozen startup companies. As a venture partner with BioAdvance, he is responsible for investments in research tools, devices, diagnostics, and digital health. His board responsibilities include Halo Labs Inc., Cohero Health Inc., WellTrackOne Inc., HealthQX LLC, Infrascan, Inc., Oncora Health Inc., and WellSheet Inc. In addition to his current board responsibilities at BioAdvance, he is also the Chairman of the advisory board of Integral Molecular Inc., and the Chairman of Pediatric Device Consortium fund at CHOP. He is also the founder and CEO of Optimeos Life Sciences, Inc., a venture funded biotech company, and former James Wei Visiting Professor of Entrepreneurship and current Lecturer in Entrepreneurship at Princeton University. Previously, Hejazi was the president of Kodak’s life science division, where he had global responsibility for R&D, manufacturing, operations, sales, marketing, and service. Before Kodak, he was the founding CEO of Zargis Medical Corporation (a Siemens' spin off ), where he led the company’s efforts in areas ranging from raising capital and technology development to completion of several clinical trials, FDA approval, and product launch. The company was later sold to 3M. Prior to that, Hejazi was the Global Head of the Strategic Business Development at Siemens Medical, responsible for identifying growth/investment opportunities and new business development in life sciences and digital health. While there, he was instrumental in establishing the Siemens corporate medical venture unit. Earlier in his career, Hejazi held R&D management positions within the imaging and nanotechnology fields at Kodak and IBM. His Past board responsibilities include FDA industry advisory panel member for Molecular and Clinical Genetic Devices, Fox Chase Cancer Center, and Alpha Innotech Corp (Nasdaq: APNO). Hejazi has a Ph.D. in electrical engineering with emphasis in biophysics (SUNY at Buffalo) and an executive business education (Stanford University).